2007

Burke RE. Kinase Signaling Pathways: Potential Therapeutic Targets in Parkinson’s Disease. Future Neurology, 2007, in press.

Burke RE.  Programmed Cell Death. In S.A. Factor and W.J.Weiner (Eds), Parkinson's Disease: Diagnosis and Clinical Management, Demos Medical Publishing, Inc., New York, in press.

Burke RE. Programmed Cell Death In Parkinson’s Disease. In: The Handbook of Clinical Neurology: Parkinson’s Disease and Related Disorders. Elsevier Limited, Edinburgh, UK, in press.

Oo TF and Burke RE. Histochemical Methods For The Detection Of Apoptosis In The Nervous System.  In C.R. Gerfen (Ed), Current Protocols in Neuroscience, John Wiley and Sons, Inc, in press, 2007.

Burke RE. Inhibition Of MAPK And Stimulation Of Akt Kinase Signaling Pathways: Two Approaches with Therapeutic Potential In The Treatment Of Neurodegenerative Disease. Pharmacology and Therapeutics, 2007, in press.
 

2006

Ries V, Henchcliffe C, Kareva T, Rzhetskaya M, Bland RJ, During MJ, Kholodilov N, Burke RE.  Oncoprotein Akt/PKB: Trophic effects in murine models of Parkinson's Disease. Proc Natl Acad Sci U S A 2006;103:18757-18762.doi:10.1073/pnas.0606401103
 

Burke RE. GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons. In: P. Riederer, H. Reichmann, M.B.H. Youdim, and M. Gerlach (Eds), Parkinson’s Disease and Related Disorders, SpringerWien, New York, 2006.

2005

Oo TF, Ries V, Cho J, Kholodilov N, Burke RE. Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat.  J Comp Neurol 2005;484:57-67.doi:10.1002/cne.20463
 

Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, Lu PD, Marciniak SM, Ron D, Przedborski S, Kholodilov N, Greene LA, Burke RE.  CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism.  J Neurochem 2005;95:974-986.doi:10.1111/j.1471-4159.2005.03428.x
 

Shakya R, Jho E-H, Kotke P, Wu Z, Kholodilov N, Burke RE, D’Agati V, Costantini F. The role of GDNF in patterning the excretory system.  Developmental Biology 2005; 283:70-84.doi:10.1016/j.ydbio.2005.04.008

Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy.  Curr Drug Targets CNS Neurol Disord 2005;4:63-67.

Silva RM, Kuan CY, Rakic P, Burke RE. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: A new therapeutic target in Parkinson's disease. Mov Disord 2005;20:653-664.

2004

Cho J, Kholodilov NG, Burke RE.  Patterns of developmental mRNA expression of neurturin and GFRalpha2 in the rat striatum and substantia nigra do not suggest a role in the regulation of natural cell death in dopamine neurons.  Dev Brain Res 2004;148:143-149.doi:10.1016/j.devbrainres.2003.11.006
 

Cho JW, Yarygina O, Kholodilov N, Burke RE.  Glial cell line-derived neurotrophic factor receptor GFRa-1 is expressed in the rat striatum during postnatal development.  Mol Br Res 2004; 127:96-104.doi:10.1016/j.molbrainres.2004.05.015
 

Ganguly A, Oo TF, Rzhetskaya M, Pratt R, Yarygina O, Momoi T, Kholodilov N, Burke RE.  CEP11004, a novel inhibitor of the mixed lineage kinases, suppresses apoptotic death in dopamine neurons of the substantia nigra induced by 6-hydroxydopamine.  J Neurochem 2004;88:469-480.
 

Kholodilov N, Yarygina O, Oo TF, Zhang H, Sulzer D, Dauer WT, Burke RE.  Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets.  J Neurosci 2004;24:3136-3146.doi:10.1523/JNEUROSCI.4506-03.2004
 

Stefanis L, Wang Q, Oo T, Lang-Rollin I, Burke RE, Dauer WT.  Lack of a-synuclein does not alter apoptosis of neonatal catecholaminergic neurons Eur J Neuroscience 2004; 20:1969-1972.doi:10.1111/j.1460-9568.2004.03638.x

Burke RE. Ontogenic cell death in the nigrostriatal system. In: Unsicker K (Ed). The Dopaminergic Nigrostriatal System: Development, Physiology, Disease. Cell and Tissue Research. 2004;318:63-72.
 

Burke RE. Recent Advances In Parkinson Disease Research: Synuclein And Parkin.  The Neurologist, 10:75-81, 2004.

Skidmore F, Weiner W, Burke RE.  Neuroleptic-induced tardive dyskinesia variants. In: Lang AE & Weiner WJ (Eds), Drug-Induced Movement Disorders, Second Edition. Futura Press, Mount Kisco, New York, 2004.

2003

Cho J, Kholodilov NG, Burke RE.  The developmental time course of Glial Cell Line-Derived Neurotrophic Factor (GDNF) and GDNF Receptor alpha-1 mRNA expression in the striatum and substantia nigra.  Ann N Y Acad Sci 2003;991:284-287.
 

Nunes I, Tovmasian LT, Silva RM, Burke RE, Goff SP.  Pitx3 is required for development of substantia nigra dopaminergic neurons.  Proc Natl Acad Sci U S A 2003;100:4245-4250.doi:10.1073/pnas.0230529100
 

Oo TF, Kholodilov N, Burke RE.  Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal GDNF in vivo.  J Neurosci 2003;23:5141-5148.
 

El-Khodor BF, Oo TF, Kholodilov N, Burke RE. Ectopic expression of cell cycle markers in models of induced programmed cell death in dopamine neurons of the rat substantia nigra pars compacta.  Exp Neurol 2003; 179:17-27.doi:10.1006/exnr.2002.8047
 

Burke RE. Postnatal Developmental Programmed Cell Death in Dopamine Neurons.  Ann N Y Acad Sci 2003;991:69-79.
 

2002

Dauer WT, Kholodilov N, Vila M, Trillat A, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke RE, Hen R.  Resistance of synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002;99:14524-14529.doi:10.1073/pnas.172514599
 

El-Khodor BF, Burke RE.  Medial forebrain bundle axotomy during development induces apoptosis in dopamine neurons of the substantia nigra and activation of caspases in their degenerating axons .  J Comp Neurol 2002;452:65-79.doi:10.1002/cne.10367
 

Marti MJ, Saura J, Burke RE, Jackson-Lewis V, Jimenez A, Bonastre M, Tolosa E.   Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat.  Brain Res 2002;958:185-191.doi:10.1016/S0006-8993(02)03694-6

Oo TF, Siman R, Burke RE.  Distinct nuclear and cytoplasmic localization of caspase cleavage products in two models of induced apoptotic death in dopamine neurons of the substantia nigra.  Exp Neurol 2002;175:1-9.doi:10.1006/exnr.2002.7881
 

Neystat M, Rzhetskaya M, Kholodilov NG, Burke RE.  Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay. Neuroscience Letters 2002; 325: 119-123.doi:10.1016/S0304-3940(02)00253-7

2001

El-Khodor BF, Kholodilov NG, Yarygina O, Burke RE.  The expression of mRNAs for the proteasome complex is developmentally regulated in the rat mesencephalon.  Brain Res Dev Brain Res 2001;129:47-56.doi:10.1016/S0165-3806(01)00181-X
 

Neystat M, Rzhetskaya M, Oo TF, Kholodilov N, Yarygina O, Wilson A, El-Khodor BF, Burke RE.  Expression of cyclin-dependent kinase 5 and its activator p35 in models of induced apoptotic death in neurons of the substantia nigra in vivo.  J Neurochem 2001;77:1611-1625.doi:10.1046/j.1471-4159.2001.00376.x
 

Stefanis L, Kholodilov N, Rideout HJ, Burke RE, Greene LA.  Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells.   J Neurochem 2001;76:1165-1176.doi:10.1046/j.1471-4159.2001.00114.x

Burke RE. a-Synuclein, Parkin, and the Pathogenesis of Parkinson's Disease: Pieces of the Puzzle Come Together The Lancet, 358:1567-8, 2001.

2000

Jackson-Lewis V, Vila M, Djaldetti R, Guegan C, Liberatore G, Liu J, O'Malley KL, Burke RE, Przedborski S.  Developmental cell death in dopaminergic neurons of the substantia nigra of mice.  J Comp Neurol 2000; 424:476-488.doi:10.1002/1096-9861(20000828)424:3<476::AID-CNE6>3.0.CO;2-0

Kholodilov NG, Neystat M, Oo TF, Hutson SM, Burke RE.  Upregulation of cytosolic branched chain aminotransferase in substantia nigra following developmental striatal target injury.  Mol Brain Res 2000;75:281-286.doi:10.1016/S0169-328X(99)00318-6

Oo TF, Burke RE. Identification of Apoptotic Morphology in Phenotypically-Defined Dopamine Neurons of the Substantia Nigra. In MM Mouradian (Ed), Methods in Molecular Medicine. Parkinson's Disease: Methods and Protocols, Humana Press, Inc., 2000.

Oo TF and Burke RE.  Animal Models of Induced Apoptotic death in the Substantia Nigra.  In MM Mouradian (Ed), Methods in Molecular Medicine. Parkinson's Disease: Methods and Protocols, Humana Press, Inc., 2000.
 

Zigmond MJ and Burke RE.  Pathophysiology of Parkinson's Disease: Basic and Clinical Studies. In D Charney, J Coyle, K Davis, C Nemeroff (Eds), Psychopharmacology: A Fifth Generation of Progress, The American College of Neuropsychopharmacology, 2000.

1999

Jeon BS, Kholodilov NG, Oo TF, Kim S, Tomaselli KJ, Srinivasan A, Stefanis L, Burke RE.  Activation of caspase-3 in developmental models of programmed cell death in neurons of the substantia nigra.   J Neurochem 1999;73:322-333.doi:10.1046/j.1471-4159.1999.0730322.x
 

Kholodilov NG, Oo TF, Burke RE.  Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine.  Neurosci Lett 1999;273:105-108.doi:10.1016/S0304-3940(99)00740-5

Kholodilov NG, Neystat M, Oo TF, Lo SE, Larsen KE, Sulzer D, Burke RE.  Increased expression of rat synuclein1 in the substantia nigra pars compacta identified by differential display in a model of developmental target injury.  J Neurochem 1999;73:2586-2599.doi:10.1046/j.1471-4159.1999.0732586.x
 

Neystat M, Lynch T, Przedborski S, Kholodilov NG, Rzhetskaya M, Burke RE. alpha-Synuclein expression in substantia nigra and cortex in Parkinson's Disease Mov Disord 1999;14:417-422.doi:10.1002/1531-8257(199905)14:3<417::AID-MDS1005>3.0.CO;2-X
 

Oo TF, Henchcliffe C, James D, Burke RE.  Expression of c-fos, c-jun, and c-jun N-terminal kinase (JNK) in a developmental model of induced apoptotic death in neurons of the substantia nigra. J Neurochem 1999; 72:557-564doi:10.1046/j.1471-4159.1999.0720557.x
 

Burke RE. Parkinson's Disease. In: Koliatsos VE, Ratan RR, eds. Cell Death and Diseases of the Nervous System. Totowa, NJ: Humana, 1999:459-475.

Burke RE. a-Synuclein and Parkinson's Disease.  In S.B. Dunnett (Ed), Highlights in Twentieth Century Neuroscience, Brain Research Bulletin 1999;50:465-466.

1998

Burke RE, Antonelli M, Sulzer D.  Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture.  J Neurochem 1998;71:517-525.

Burke RE. Apoptosis in degenerative diseases of the basal ganglia.  The Neuroscientist 1998;4:301-311.

Burke RE, Kholodilov NG.  Programmed cell death: does it play a role in Parkinson's disease?  Ann Neurol 1998;44:S126-S133.

Burke RE.  Programmed cell death and Parkinson's Disease.  In Fahn S, Burke RE, Mayeux R, Prezedborski S (Eds), Movement Disorders, 1998; 13 (Supp 1):17-23.

Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia.  Brain 1998;121:547-560.

1997

Marti MJ, James CJ, Oo TF, Kelly WJ, Burke RE.  Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra.  J Neurosci 1997;17: 2030-2039.
 

Oo TF, Burke RE.  The time course of developmental cell death in phenotypically defined dopaminergic neurons of the substantia nigra.  Dev Brain Res 1997;98:191-196.doi:10.1016/S0165-3806(96)00173-3
 

Stefanis L, Burke RE, Greene LA. Apoptosis in neurodegenerative disorders. Current Opinion in Neurology 1997;10:299-305.

Henchcliffe C. , Burke RE. Increased expression of cyclin-dependent kinase 5 in induced apoptotic Neuroscience Letters 230 (1997) 41–44
 

1996

Kelly WJ, Burke RE.  Apoptotic neuron death in rat substantia nigra induced by striatal excitotoxic injury is developmentally dependent. Neurosci Lett 1996;220:85-88.doi:10.1016/S0304-3940(96)13216-X

Oo TF, Blazeski R, Harrison SMW, Henchcliffe C, Mason CA, Roffler-Tarlov S, Burke RE..  Neuron death in the substantia nigra of weaver mouse occurs late in development and is not apoptotic J Neurosci 1996;16:6134-6145.
 

Oo TF, Naini A, Burke RE.  Augmented pharmacologic stimulation of striatal acetylcholine release following developmental hypoxic-ischemic injury.  Brain Res 1996;706:145-150.doi:10.1016/0006-8993(95)01240-0

Stefanis L, Burke RE.  Transneuronal degeneration in substantia nigra pars reticulata following striatal excitotoxic injury in adult rat: Time course, distribution, and morphology of cell death.. Neuroscience 1996;74:997-1008

Burke RE.  Tardive akathisia.  In: Yassa R and Jeste D (Eds), Neuroleptic-induced Movement Disorders. Cambridge University Press, Cambridge, England, 1996.

1995

Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine.  Neurodegen 1995;4:257-269.doi:10.1016/1055-8330(95)90015-2

Jeon BS, Jackson-Lewis V, Burke RE. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death.  Neurodegen 1995;4:131-137.doi:10.1006/neur.1995.0016

Oo TF, Henchcliffe C, Burke RE.  Apoptosis in substantia nigra following developmental hypoxic-ischemic injury.  Neuroscience 1995;69:893-901.doi:10.1016/0306-4522(95)00282-N

1994

Burke RE, Franklin SO, Inturrisi CE.  Acute and persistent suppression of preproenkephalin mRNA expression in the striatum following developmental hypoxic- ischemic injury.. J Neurochem 1994;62:1878-1886

Macaya A, Munell F, Gubits RM, Burke RE.  Apoptosis in substantia nigra following developmental striatal excitotoxic injury.  Proc Natl Acad Sci USA 1994;91:8117-8121.doi:10.1073/pnas.91.17.8117
 

Munell F, Burke RE, Bandele A, Gubits RM.  Localization of c-fos, c-jun, and hsp70 mRNA expression in brain after neonatal hypoxia-ischemia.  Dev Brain Res 1994;77:111-121.doi:10.1016/0165-3806(94)90218-6

1993

Burke RE, Baimbridge KG.  Relative loss of the striatal striosome compartment, defined by calbindin-D28k immunostaining, following developmental hypoxic- ischemic injury. Neuroscience 1993;56:305-315.doi:10.1016/0306-4522(93)90333-B

Gubits RM, Burke RE, Casey McIntosh G, Bandele A, Munell F.   Immediate early gene induction after neonatal hypoxia-ischemia.  Mol Brain Res 1993;18:228-238.doi:10.1016/0169-328X(93)90194-T

Janec E, Burke RE.  Naturally occurring cell death during postnatal development of the substantia nigra of the rat. Mol Cell Neurosci 1993;4:30-35.doi:10.1006/mcne.1993.1004
 

Zhu YS, Jones SB, Burke RE, Franklin SO, Inturrisi CE.  Quantitation of the levels of tyrosine hydroxylase and preproenkephalin mRNAs in nigrostriatal sites after 6- hydroxydopamine lesions.  Life Sci 1993;52:1577-1584.doi:10.1016/0024-3205(93)90058-B

Giladi N, Burke RE. Hemiparkinsonism-Hemiatrophy syndrome.  In: Koller WC, Stern MB (Eds), Parkinsonian Syndromes. Marcel Dekker, Inc, New York, NY, 1993.

1992

Burke RE, Macaya A, DeVivo D, Kenyon N, Janec EM.  Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons.  Neuroscience 1992;50:559-569.doi:10.1016/0306-4522(92)90447-A

Macaya A, Burke RE.  Effect of striatal lesion with quinolinate on the development of substantia nigra dopaminergic neurons: a quantitative morphological analysis. Dev Neurosci 1992;14:362-368.

Burke, RE. Movement Disorders. In: Kaufman DM, Solomon GE, Pfeffer C (Eds). Pediatric Neurology for Psychiatrists. Williams and Wilkins, Baltimore, 1992.

Burke, RE.  Neuroleptic-induced tardive dyskinesia variants.  In: Lang AE & Weiner WJ (Eds), Drug-Induced Movement Disorders. Futura Press, Mount Kisco, New York, 1992.

Burke RE. Neuromuscular effects of neuroleptics: Dystonia. In: Lieberman J & Kane J (Eds), Adverse Effects of Psychotropic Drugs. Guilford Publications, Inc., New York, New York, 1992.

1991

Burke RE, Reches A.   Preserved striatal tyrosine hydroxylase activity, assessed in vivo, following neonatal hypoxia-ischemia.  Dev Brain Res 1991;61:277-280.doi:10.1016/0165-3806(91)90143-7

Burke RE, Kenyon N.  The effect of neonatal hypoxia-ischemia on striatal cholinergic neuropil: a quantitative morphologic analysis.  Exp Neurol 1991;113:63-73.doi:10.1016/0014-4886(91)90147-5

Burke RE, Kent J, Kenyon N, Karanas A.  Unilateral hypoxic-ischemic injury in neonatal rat results in a persistent increase in the density of striatal tyrosine hydroxylase immunoperoxidase staining.  Dev Brain Res 1991;58:171-179.doi:10.1016/0165-3806(91)90003-2

Kostic V, Przedborski S, Jackson Lewis V, Cadet JL, Burke RE.  Effect of unilateral perinatal hypoxic-ischemic brain injury in the rat on striatal muscarinic cholinergic receptors and high- affinity choline uptake sites: a quantitative autoradiographic study.  J Neurochem 1991;57:1962-1970doi:10.1111/j.1471-4159.1991.tb06410.x

Kostic VS, Przedborski S, Jackson Lewis V, Cadet JL, Burke RE. Effect of unilateral perinatal hypoxic-ischemic brain injury on striatal dopamine uptake sites and D1 and D2 receptors in adult rats.  Neurosci Lett 1991;129:197-200.doi:10.1016/0304-3940(91)90460-B

Pezzoli G, Zecchinelli A, Ricciardi S, Burke RE, Fahn S, Scarlato G, Carenzi A.  Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats.  Mov Disord 1991;6:281-287.doi:10.1002/mds.870060403

Przedborski S, Kostic V, Jackson Lewis V, Cadet JL, Burke RE.  Effect of unilateral perinatal hypoxic-ischemic brain injury in the rat on dopamine D1 and D2 receptors and uptake sites: a quantitative autoradiographic study.  J Neurochem 1991;57:1951-1961.doi:10.1111/j.1471-4159.1991.tb06409.x

Saint Hilaire MH, Burke RE, Bressman SB, Brin MF, Fahn S.  Delayed-onset dystonia due to perinatal or early childhood asphyxia.  Neurology 1991;41:216-222.

1990

Burke RE, Karanas AL.  Quantitative morphological analysis of striatal cholinergic neurons in perinatal asphyxia.  Ann Neurol 1990;27:81-88.doi:10.1002/ana.410270113

Burke RE, Cadet JL, Kent JD, Karanas AL, Jackson Lewis V.  An assessment of the validity of densitometric measures of striatal tyrosine hydroxylase-positive fibers: relationship to apomorphine-induced rotations in 6-hydroxydopamine lesioned rats. J Neurosci Methods 1990;35:63-73.doi:10.1016/0165-0270(90)90095-W

Burke RE, Karanas AL.  Demonstration of a medial to lateral gradient in the density of cholinergic neuropil in the rat striatum.  Neurosci Lett 1990;108:58-64.doi:10.1016/0304-3940(90)90706-F

Giladi N, Burke RE, Kostic V, Przedborski S, Gordon M, Hunt A, Fahn S. Hemiparkinsonism-hemiatrophy syndrome: clinical and neuroradiologic features. Neurology 1990;40:1731-1734.

1989

Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S.  Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-175.doi:10.1002/mds.870040208

Ozelius L, Kramer P, Moskowitz CB, Kwiatkowski DJ, Brin MF, Bressman SB, Schuback DE, Falk CT, Risch N, de Leon D, Burke RE, Haines J, Gusella JF, Fahn S, Breakefield XO.  Human gene for torsion dystonia located on chromosome 9q32-q34.  Neuron 1989;2:1427-1434doi:10.1016/0896-6273(89)90188-8

1988

Burke RE, Kang UJ.  Tardive dystonia: clinical aspects and treatment.  In : J Jankovic and E Tolosa (Eds), Facial Dyskinesias, Advances in Neurology, Raven Press, New York, 1988;49:199-210.

Burke RE, Fahn S. An evaluation of sustained postural abnormalities in rats induced by intracerebro-ventricular injection of chlorpromazine methiodide or somatostatin as models of dystonia.  In: S Fahn, CD Marsden, DB Calne (Eds), Dystonia 2 Advances in Neurology, Raven Press, New York, 1988;50:335-342.

1986

Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high- dosage trihexyphenidyl.  Neurology 1986;36:160-164.

Burke RE, Brin MF, Fahn S, Bressman SB, Moskowitz C.  Analysis of the clinical course of non-Jewish, autosomal dominant torsion dystonia.  Mov Disord 1986;1:163-178.doi:10.1002/mds.870010302

1985

Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J.  Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73-77.

Burke RE, Fahn S.   Pharmacokinetics of trihexyphenidyl after short-term and long- term administration to dystonic patients.  Ann Neurol 1985;18:35-40.doi:10.1002/ana.410180107

Burke RE, Fahn S.  Serum trihexyphenidyl levels in the treatment of torsion dystonia.  Neurology 1985;35:1066-1069.

Burke RE, Reches A, Traub MM, Ilson J, Swash M, Fahn S. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-202.doi:10.1002/ana.410170217

1984

Burke RE. Tardive dyskinesia: current clinical issues.  Neurology 1984;34:1348-1353.

1983

Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia.  Adv Neurol 1983;37:189-192.

1982

Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J.  Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs.  Neurology 1982;32:1335-1346.

1980

Burke RE, Fahn S, Gold AP.  Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry 1980; 43:789-797.